300298.SZ
三诺生物
SZSE · Healthcare · C 制造业 · CN
CNY 15.91
−0.87%Year over year
Reported trailing growth
- Revenue
- +8.6%
- EBITDA
- —
- EBIT
- -76.9%
- EPS
- -62.3%
- Free cash flow
- -62.5%
- Operating cash flow
- -47.2%
Forward estimates
Based on analyst estimates
- Revenue
- -73.7%
- EBITDA
- -47.6%
- EPS
- -39.8%
Three-year CAGR
- Revenue
- +5.6%
- EBITDA
- -22.9%
- EBIT
- -44.6%
- Net income
- -40.8%
- EPS
- -40.5%
- Free cash flow
- +3.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026